Risk factors for immune checkpoint inhibitor-related interstitial lung disease: a retrospective cohort study
- 9 June 2026
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (11) , 1-8
Abstract
Immune checkpoint inhibitors (ICIs) for cancer treatment show a high incidence of immune-related adverse events (irAEs), among which severe interstitial lung disease (ILD) can be fatal, requiring prompt identification and management. This study aimed to identify pre-treatment risk factors associated with ICI-induced ILD. Medical records of patients who received ICIs were retrospectively reviewed. Age, sex, body weight, primary tumor type, ICI agent, PD-L1 status, disease stage, line of treatment, and laboratory parameters measured before treatment initiation were collected. Smoking history and prior diagnoses of chronic obstructive pulmonary disease and ILD were recorded. Patients who developed ILD were compared with those who did not. Elevated pre-treatment C-reactive protein (CRP) levels (odds ratio [OR] = 1.877; 95% confidence interval [CI] = 1.238–2.845; p = 0.003) and increased monocyte counts (OR = 23.509; 95% CI = 1.375–4.020 × 102; p = 0.029) were potential risk factors for ILD development following ICI therapy. A multivariable logistic regression model incorporating pre-ICI CRP levels and monocyte counts was constructed to predict ILD risk. The receiver operating characteristic analysis of this model yielded an area under the curve of 0.808 with a sensitivity of 92.0% and a specificity of 63.9%. Elevated pre-treatment levels of CRP and monocytes were significantly associated with the subsequent ILD development in patients treated with ICIs. These findings underscore the importance of close monitoring for pulmonary toxicity in patients with elevated CRP and monocyte counts before initiating ICI therapy.Keywords
This publication has 31 references indexed in Scilit:
- Single-cell landscape of bronchoalveolar immune cells in patients with immune checkpoint inhibitor-related pneumonitisnpj Precision Oncology, 2024
- Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarksCell Death & Disease, 2024
- Immune-checkpoint inhibitors: long-term implications of toxicityNature Reviews Clinical Oncology, 2022
- Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective studyScientific Reports, 2020
- Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicitiesProceedings of the National Academy of Sciences, 2019
- C-reactive protein as an early marker of immune-related adverse eventsJournal of Cancer Research and Clinical Oncology, 2019
- Immune checkpoint inhibitors: recent progress and potential biomarkersExperimental & Molecular Medicine, 2018
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- Immune Checkpoint Immunotherapy for Non-Small Cell Lung CancerChest, 2018
- IL-6 pathway in the liver: From physiopathology to therapyJournal of Hepatology, 2016